MRD Welcome Faculty & Guests Dinner

Breakfast & Registration 

Live welcome & introduction
Ola Landgren 

Session I:MRD testing in smoldering myeloma: new horizons!
Chair: TBC

• From CENTAURUS to AQUILA trials: Thanos Dimopoulos, Greece
• NCI KRd-R trial long-term follow up: Elizabeth Hill, National Cancer Institute
• ASCENT trial: Shaji Kumar, Mayo Clinic
• Immuno-PRISM and CAR-PRISM trials: Omar Nadeem, Dana-Farber Cancer Institute
• REVIVE trial: Ola Landgren, University of Miami 

Panel discussion (10 minutes): Thanos Dimopoulos Elizabeth Hill, Shaji Kumar, Omar Nadeem, Ola Landgren, Malin Hultcrantz, Hans Lee, Paula Neri, Adam Cohen

Session II: Panel discussion – Is high-risk SMM the new treatment indication for all patients? Role of depth of response?
Panel chair: Ola Landgren

Discussants: Nicole Gormley (FDA),  TBC (patient advocates), Joseph Mikhael, Malin Hultcrantz & TBC (physicians)

Break & Exhibition

Session III: New insights on MRD negativity in newly diagnosed myeloma                                                              
Chair: Benjamin Diamond, University of Miami

• MANHATTAN trial, long-term update: TBC
• MagnetisMM-6 trial, part 2: Hang Quach, University of Melbourne, Australia
• IFM2021-01 TecLille trial: Salomon Manier, Lille University Hospital, France 
• MajesTEC-5 trial: TBC
• ADVANCE 2.0 trial: Kellye Koubek, University of Miami 

Panel discussion (10 minutes): Hang Quach, Salomon Manier,  Kellye Koubek & TBC

SESSION IV: Panel discussion – Newly diagnosed multiple myeloma and MRD: What are the trends?

Panel chair: Ola Landgren

Panel with Joseph Mikhael (IMF) and Hearn Jay Cho (MMRF), Nicole Gormley (FDA), Gareth Morgan, Charlotte Pawlyn and TBC

Session V: MRD driven treatment trials
Chair:  Rafat Abonour, University of Miami

Panel discussion (10 minutes): Brian Walker, Adam Cohen, Dickran Kazandijan, Shaji Kumar, Bob Orlowski, Niels Weinhold, Malin Hultcrantz,
Tomas Jelinek and Ben Diamond

LUNCH & FIRESIDE-CHAT

DR. NICOLE GORMLEY, FDA & DR. OLA LANDGREN, UNIVERSITY OF MIAMI

Session VI: Panel discussion – MRD and treatment decisions: Are we there yet?

Panel chair: Damian Green, University of Miami (“today and the future”)

Panel with: Joseph Mikhael (IMF), and Hearn Jay Cho (MMRF) and TBC (HealthTree)

Session VII: CMRD in relapsed/refractory myeloma
Chair:  Ben Diamond, University of Miami

• DREAMM-7 trial: Vania Hungria, Clínica São Germano, São Paulo, Brazil
• ARLOCEL trial with MEZI: Susan Bal, University of Alabama
• REKINDLE trial: Benjamin Diamond, University of Miami
• FAST CAR-T trial: Juan Du
• LINKER-MM4 trial: TBC
• Redirectt-1 trial: TBC
• iMMagine-1 trial: TBC
  

Panel discussion (10 minutes): Vania Hungria, Susan Bal, Juan Du, Adam Cohen,  Marlin Hultcrantz and TBC

Coffee Break & Exhibition

Session IX: Emerging MRD technologies
Chair: David Coffey, University of Miami 

• Update on ClonoSEQ MRD data, Malin Hultcrantz, MSKCC
• Cell free DNA tracking: Ben Diamond, University of Miami
• Predicta assay: Irene Ghobrial, Dana-Farber Cancer Institute
• Update on MALDI TOF MS and clonotypic peptides, TBC
• Update on FLC tracking: Kazunori Murata, University of Miami
• CD38 targeted immunoPET: TBC

Panel discussion (10 minutes): Malin Hultcrantz, Ben Diamond, Irene Ghobrial, Kazunori Murata, Bob Orlowski, Gareth Morgan, Larry Boise & TBC

Session X: Emerging MRD technologies: What are the clinical and scientific needs?

Panel Chair: Ola Landgren

Panel with: TBC (HeathTree), Joseph Mikhael (IMF) and George Mullligan (MMRF)

Wrap up and Adjourn

Ola Landgren, TBC (HealthTree), Joseph Mikhael (IMF), George Mulligan (MMRF)

Exhibition, reception & refreshments